Ascletis Pharma Inc. (ASCLETIS-B) filed its Monthly Return for the period ended 30 June 2026, reporting no changes in either authorised or issued share capital during the month.

Authorised and Issued Share Capital • Authorised share capital stood unchanged at 7.00 billion ordinary shares with a par value of USD 0.0001 each, amounting to USD 0.70 million. • Total issued shares remained at 1.07 billion, of which 1.06 billion are outstanding and 7.08 million are held as treasury shares. • No new shares were issued, and no treasury shares were cancelled or re-allotted in June.

Public Float Compliance • Ascletis confirmed compliance with the Main Board’s Initial Prescribed Threshold, maintaining a public float of at least 25% of issued share capital (excluding treasury shares) as at 30 June 2026.

Share Option Schemes • 2019 Share Option Scheme: 6.36 million options outstanding; 2.85 million shares remain available for future issue. • 2025 Share Option Scheme: 5.47 million options outstanding; 1.21 million shares remain available for issue, with capacity to grant up to 33.09 million additional shares. • No options were exercised in June, resulting in zero proceeds from option exercises.

Share Repurchases Pending Cancellation • The company has 9.53 million repurchased shares awaiting cancellation, comprising: – 0.80 million repurchased in April 2025 – 8.59 million repurchased between October 2025 and June 2026 – 0.15 million repurchased on 30 June 2026

Other Instruments • The issuer reported no outstanding warrants, convertible securities, or other agreements that could dilute equity.

Overall, Ascletis Pharma’s June 2026 filing highlights a steady equity position with continued adherence to Hong Kong Listing Rules on public float and transparent disclosure of share repurchase activity.